Exact Mass: 548.2529246
Exact Mass Matches: 548.2529246
Found 500 metabolites which its exact mass value is equals to given mass value 548.2529246,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Antimycin A
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents D000890 - Anti-Infective Agents > D000935 - Antifungal Agents
Tamoxifen-N-glucuronide
Tamoxifen-N-glucuronide is a metabolite of tamoxifen. Tamoxifen is an antagonist of the estrogen receptor in breast tissue via its active metabolite, hydroxytamoxifen. In other tissues such as the endometrium, it behaves as an agonist, and thus may be characterized as a mixed agonist/antagonist. Tamoxifen is the usual endocrine therapy for hormone receptor-positive breast cancer in pre-menopausal women, and is also a standard in post-menopausal women although aromatase inhibitors are also frequently used in that setting. (Wikipedia)
Murabutide
Trh-gly-lys
D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones
Murabutida
PA(2:0/PGE2)
PA(2:0/PGE2) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/PGE2), in particular, consists of one chain of one acetyl at the C-1 position and one chain of Prostaglandin E2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(PGE2/2:0)
PA(PGE2/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGE2/2:0), in particular, consists of one chain of one Prostaglandin E2 at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(2:0/PGD2)
PA(2:0/PGD2) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/PGD2), in particular, consists of one chain of one acetyl at the C-1 position and one chain of Prostaglandin D2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(PGD2/2:0)
PA(PGD2/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGD2/2:0), in particular, consists of one chain of one Prostaglandin D2 at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(2:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S))
PA(2:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of Lipoxin A4 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/2:0)
PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/2:0), in particular, consists of one chain of one Lipoxin A4 at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
Baccharinoid B 20
[7R(R)]-2-Deoxy-7-deoxo-4,16-dihydroxy-7-(1-hydroxyethyl)verrucarin A
[7R(R)]-7-Deoxo-16-hydroxy-7-(1-hydroxyethyl)verrucarin A
6R,7E,9R-megastigma-4,7-dien-3-one 9,13-di-O-beta-D-glucopyranoside
[2R,7R(S),8R]-7-Deoxo-8-hydroxy-7-(1-hydroxyethyl)verrucarin A
4,8-dihydroxy-3-methoxy-11-oxo-1,6-dipentyl-11H-dibenzo[b,e][1,4]dioxepine-7-carboxylic acid benzyl ester
(Ra)-3-phenylacrylic acid 7-hydroxy-2,3,10,11,12-pentamethoxy-6,7-dimethyl-5,6,7,8-tetrahydrodibenzo[a,c]cycloocten-1-yl ester|neglschisandrin C
8,9,10,22-tetrahydroxy-7,18-dimethyl-19-(5-oxo-2H-furan-3-yl)-4,6,11-trioxahexacyclo[12.11.0.03,12.05,10.015,23.018,22]pentacosane-14-carbaldehyde
3-O-(2,6-Dideoxy-beta-D-xylo-hexopyranoside)-3,5,11,14-Tetrahydroxy-19-oxocarda-6,20(22)-dienolide
3-Angeloyl,8-(2-methylbutanoyl),14,15-di-Ac-(3beta,8beta,9beta)-14,15-Epoxy-4-isocedrene-3,8,9,14,15-pentol
3-(hexopyranosyloxy)-14-hydroxy-19-oxocarda-5,20(22)-dienolide
(3S,5S)-1,7-bis(3,4,5-trimethoxyphenyl)heptane-3,5-diyl diacetate|(3S,5S)-3,5-diacetoxy-1,7-bis(3,4,5-trimethoxyphenyl)heptane
(4beta,5beta,6alpha,18R,22R)-6-chloro-18,20-epoxy-18-ethoxy-4,5,22-trihydroxy-1-oxoergost-2,24-dien-26-oic acid gamma-lactone|withaphysalin U
6,9-dihydroxymegastigmasta-5,7-dien-3-one 9-O-beta-D-gentiobioside
3-(3-formamido-2-hydroxybenzamido)-8-pentyl-2,6-dimethyl-4,9-dioxo-1,5-dioxonan-7-yl 2,3-dimethylbutanoate|antimycin A19
(20S,22R)-15alpha-acetoxy-5alpha-chloro-6beta,14beta-dihydroxy-1-oxowitha-2,24-dienolide|(5alpha,6beta,14beta,15alpha,22R)-5-chloro-6,14-dihydroxy-1,26-dioxo-22,26-epoxyergosta-2,24-dien-15-yl acetate
bistratamide I
A homodetic cyclic peptide that consists of L-valine and L-threonine as the amino acid residues. It is isolated from Lissoclinum bistratum and exhibits antitumour activity against the human colon tumour cell line.
rel-(3aR,5aS,6S,7aR,7bS,11R,11aR,12aS,13aR)-11-[(2R,3R,5R,8S)-3,8-dimethyl-7-oxo-1,6-dioxaspiro[4.4]non-2-yl]-tetradecahydro-6,12a-dihydroxy-5,5,11-trimethyl-2H,9H-furo[3,2:2,3]furo[3,4:5,6]azuleno[1,2-b]pyran-2,9-dione|schintrilactone C
(22S,23R)-5alpha-chloro-12alpha,22-epoxy-12beta-ethoxy-6beta,17beta-dihydroxy-1-oxowitha-2,24-dien-26,23-olide|12-O-ethyljaborosalactone 42
Animicin A
relative retention time with respect to 9-anthracene Carboxylic Acid is 1.578 D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents D000890 - Anti-Infective Agents > D000935 - Antifungal Agents relative retention time with respect to 9-anthracene Carboxylic Acid is 1.579 relative retention time with respect to 9-anthracene Carboxylic Acid is 1.582
Antimycin A
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents D000890 - Anti-Infective Agents > D000935 - Antifungal Agents A nine-membered bis-lactone having methyl substituents at the 2- and 6-positions, an n-hexyl substituent at the 8-position, an acyloxy substituent at the 7-position and an aroylamido substituent at the 3-position. It is produced by Streptomyces bacteria and has found commercial use as a fish poison.
C29H40O10_7aH,13aH-Cyclopenta[7,8]phenanthro[2,3-b]pyrano[3,2-e][1,4]dioxin-13a-carboxaldehyde, 1-(2,5-dihydro-5-oxo-3-furanyl)eicosahydro-1,3a,11,11a-tetrahydroxy-9,15a-dimethyl-, (1S,3aS,3bR,6aR,9R,11R,11aS,12aR,13aR,15aS)
Ala Ser Trp Trp
Ala Trp Ser Trp
Ala Trp Trp Ser
Cys Asp Arg Arg
C19H36N10O7S (548.2489026000001)
Cys Ile Gln Trp
Cys Ile Trp Gln
Cys Leu Gln Trp
Cys Leu Trp Gln
Cys Gln Ile Trp
Cys Gln Leu Trp
Cys Gln Trp Ile
Cys Gln Trp Leu
Cys Arg Asp Arg
C19H36N10O7S (548.2489026000001)
Cys Arg Arg Asp
C19H36N10O7S (548.2489026000001)
Cys Trp Ile Gln
Cys Trp Leu Gln
Cys Trp Gln Ile
Cys Trp Gln Leu
Asp Cys Arg Arg
C19H36N10O7S (548.2489026000001)
Asp Lys Met Arg
C21H40N8O7S (548.2740530000001)
Asp Lys Arg Met
C21H40N8O7S (548.2740530000001)
Asp Lys Thr Trp
Asp Lys Trp Thr
Asp Met Lys Arg
C21H40N8O7S (548.2740530000001)
Asp Met Gln Arg
Asp Met Arg Lys
C21H40N8O7S (548.2740530000001)
Asp Met Arg Gln
Asp Gln Met Arg
Asp Gln Arg Met
Asp Arg Cys Arg
C19H36N10O7S (548.2489026000001)
Asp Arg Lys Met
C21H40N8O7S (548.2740530000001)
Asp Arg Met Lys
C21H40N8O7S (548.2740530000001)
Asp Arg Met Gln
Asp Arg Gln Met
Asp Arg Arg Cys
C19H36N10O7S (548.2489026000001)
Asp Thr Lys Trp
Asp Thr Trp Lys
Asp Trp Lys Thr
Asp Trp Thr Lys
Glu Lys Ser Trp
Glu Lys Trp Ser
Glu Met Asn Arg
Glu Met Arg Asn
Glu Asn Met Arg
Glu Asn Arg Met
Glu Arg Met Asn
Glu Arg Asn Met
Glu Ser Lys Trp
Glu Ser Trp Lys
Glu Trp Lys Ser
Glu Trp Ser Lys
Phe Phe His Val
Phe Phe Val His
Phe His Phe Val
Phe His Val Phe
Phe Val Phe His
Phe Val His Phe
Gly Met Arg Trp
Gly Met Trp Arg
Gly Arg Met Trp
Gly Arg Trp Met
Gly Thr Trp Trp
Gly Trp Met Arg
Gly Trp Arg Met
Gly Trp Thr Trp
Gly Trp Trp Thr
His Phe Phe Val
His Phe Val Phe
His His Gln Gln
C22H32N10O7 (548.2455322000001)
His Met Val Tyr
His Met Tyr Val
His Gln His Gln
C22H32N10O7 (548.2455322000001)
His Gln Gln His
C22H32N10O7 (548.2455322000001)
His Val Phe Phe
His Val Met Tyr
His Val Tyr Met
His Tyr Met Val
His Tyr Val Met
Ile Cys Gln Trp
Ile Cys Trp Gln
Ile Gln Cys Trp
Ile Gln Trp Cys
Ile Trp Cys Gln
Ile Trp Gln Cys
Lys Asp Met Arg
C21H40N8O7S (548.2740530000001)
Lys Asp Arg Met
C21H40N8O7S (548.2740530000001)
Lys Asp Thr Trp
Lys Asp Trp Thr
Lys Glu Ser Trp
Lys Glu Trp Ser
Lys Met Asp Arg
C21H40N8O7S (548.2740530000001)
Lys Met Arg Asp
C21H40N8O7S (548.2740530000001)
Lys Arg Asp Met
C21H40N8O7S (548.2740530000001)
Lys Arg Met Asp
C21H40N8O7S (548.2740530000001)
Lys Ser Glu Trp
Lys Ser Trp Glu
Lys Thr Asp Trp
Lys Thr Trp Asp
Lys Trp Asp Thr
Lys Trp Glu Ser
Lys Trp Ser Glu
Lys Trp Thr Asp
Leu Cys Gln Trp
Leu Cys Trp Gln
Leu Gln Cys Trp
Leu Gln Trp Cys
Leu Trp Cys Gln
Leu Trp Gln Cys
Met Asp Lys Arg
C21H40N8O7S (548.2740530000001)
Met Asp Gln Arg
Met Asp Arg Lys
C21H40N8O7S (548.2740530000001)
Met Asp Arg Gln
Met Glu Asn Arg
Met Glu Arg Asn
Met Gly Arg Trp
Met Gly Trp Arg
Met His Val Tyr
Met His Tyr Val
Met Lys Asp Arg
C21H40N8O7S (548.2740530000001)
Met Lys Arg Asp
C21H40N8O7S (548.2740530000001)
Met Asn Glu Arg
Met Asn Arg Glu
Met Asn Val Trp
Met Asn Trp Val
Met Gln Asp Arg
Met Gln Arg Asp
Met Arg Asp Lys
C21H40N8O7S (548.2740530000001)
Met Arg Asp Gln
Met Arg Glu Asn
Met Arg Gly Trp
Met Arg Lys Asp
C21H40N8O7S (548.2740530000001)
Met Arg Asn Glu
Met Arg Gln Asp
Met Arg Trp Gly
Met Val His Tyr
Met Val Asn Trp
Met Val Trp Asn
Met Val Tyr His
Met Trp Gly Arg
Met Trp Asn Val
Met Trp Arg Gly
Met Trp Val Asn
Met Tyr His Val
Met Tyr Val His
Asn Glu Met Arg
Asn Glu Arg Met
Asn Met Glu Arg
Asn Met Arg Glu
Asn Met Val Trp
Asn Met Trp Val
Asn Pro Arg Tyr
Asn Pro Tyr Arg
Asn Arg Glu Met
Asn Arg Met Glu
Asn Arg Pro Tyr
Asn Arg Tyr Pro
Asn Val Met Trp
Asn Val Trp Met
Asn Trp Met Val
Asn Trp Val Met
Asn Tyr Pro Arg
Asn Tyr Arg Pro
Pro Asn Arg Tyr
Pro Asn Tyr Arg
Pro Arg Asn Tyr
Pro Arg Tyr Asn
Pro Tyr Asn Arg
Pro Tyr Arg Asn
Gln Cys Ile Trp
Gln Cys Leu Trp
Gln Cys Trp Ile
Gln Cys Trp Leu
Gln Asp Met Arg
Gln Asp Arg Met
Gln His His Gln
C22H32N10O7 (548.2455322000001)
Gln His Gln His
C22H32N10O7 (548.2455322000001)
Gln Ile Cys Trp
Gln Ile Trp Cys
Gln Leu Cys Trp
Gln Leu Trp Cys
Gln Met Asp Arg
Gln Met Arg Asp
Gln Gln His His
C22H32N10O7 (548.2455322000001)
Gln Arg Asp Met
Gln Arg Met Asp
Gln Trp Cys Ile
Gln Trp Cys Leu
Gln Trp Ile Cys
Gln Trp Leu Cys
Arg Cys Asp Arg
C19H36N10O7S (548.2489026000001)
Arg Cys Arg Asp
C19H36N10O7S (548.2489026000001)
Arg Asp Cys Arg
C19H36N10O7S (548.2489026000001)
Arg Asp Lys Met
C21H40N8O7S (548.2740530000001)
Arg Asp Met Lys
C21H40N8O7S (548.2740530000001)
Arg Asp Met Gln
Arg Asp Gln Met
Arg Asp Arg Cys
C19H36N10O7S (548.2489026000001)
Arg Glu Met Asn
Arg Glu Asn Met
Arg Gly Met Trp
Arg Gly Trp Met
Arg Lys Asp Met
C21H40N8O7S (548.2740530000001)
Arg Lys Met Asp
C21H40N8O7S (548.2740530000001)
Arg Met Asp Lys
C21H40N8O7S (548.2740530000001)
Arg Met Asp Gln
Arg Met Glu Asn
Arg Met Gly Trp
Arg Met Lys Asp
C21H40N8O7S (548.2740530000001)
Arg Met Asn Glu
Arg Met Gln Asp
Arg Met Trp Gly
Arg Asn Glu Met
Arg Asn Met Glu
Arg Asn Pro Tyr
Arg Asn Tyr Pro
Arg Pro Asn Tyr
Arg Pro Tyr Asn
Arg Gln Asp Met
Arg Gln Met Asp
Arg Arg Cys Asp
C19H36N10O7S (548.2489026000001)
Arg Arg Asp Cys
C19H36N10O7S (548.2489026000001)
Arg Ser Thr Trp
Arg Ser Trp Thr
Arg Thr Ser Trp
Arg Thr Trp Ser
Arg Trp Gly Met
Arg Trp Met Gly
Arg Trp Ser Thr
Arg Trp Thr Ser
Arg Tyr Asn Pro
Arg Tyr Pro Asn
Ser Ala Trp Trp
Ser Glu Lys Trp
Ser Glu Trp Lys
Ser Lys Glu Trp
Ser Lys Trp Glu
Ser Arg Thr Trp
Ser Arg Trp Thr
Ser Thr Arg Trp
Ser Thr Trp Arg
Ser Trp Ala Trp
Ser Trp Glu Lys
Ser Trp Lys Glu
Ser Trp Arg Thr
Ser Trp Thr Arg
Ser Trp Trp Ala
Thr Asp Lys Trp
Thr Asp Trp Lys
Thr Gly Trp Trp
Thr Lys Asp Trp
Thr Lys Trp Asp
Thr Arg Ser Trp
Thr Arg Trp Ser
Thr Ser Arg Trp
Thr Ser Trp Arg
Thr Trp Asp Lys
Thr Trp Gly Trp
Thr Trp Lys Asp
Thr Trp Arg Ser
Thr Trp Ser Arg
Thr Trp Trp Gly
Val Phe Phe His
Val Phe His Phe
Val His Phe Phe
Val His Met Tyr
Val His Tyr Met
Val Met His Tyr
Val Met Asn Trp
Val Met Trp Asn
Val Met Tyr His
Val Asn Met Trp
Val Asn Trp Met
Val Trp Met Asn
Val Trp Asn Met
Val Tyr His Met
Val Tyr Met His
Trp Ala Ser Trp
Trp Ala Trp Ser
Trp Cys Ile Gln
Trp Cys Leu Gln
Trp Cys Gln Ile
Trp Cys Gln Leu
Trp Asp Lys Thr
Trp Asp Thr Lys
Trp Glu Lys Ser
Trp Glu Ser Lys
Trp Gly Met Arg
Trp Gly Arg Met
Trp Gly Thr Trp
Trp Gly Trp Thr
Trp Ile Cys Gln
Trp Ile Gln Cys
Trp Lys Asp Thr
Trp Lys Glu Ser
Trp Lys Ser Glu
Trp Lys Thr Asp
Trp Leu Cys Gln
Trp Leu Gln Cys
Trp Met Gly Arg
Trp Met Asn Val
Trp Met Arg Gly
Trp Met Val Asn
Trp Asn Met Val
Trp Asn Val Met
Trp Gln Cys Ile
Trp Gln Cys Leu
Trp Gln Ile Cys
Trp Gln Leu Cys
Trp Arg Gly Met
Trp Arg Met Gly
Trp Arg Ser Thr
Trp Arg Thr Ser
Trp Ser Ala Trp
Trp Ser Glu Lys
Trp Ser Lys Glu
Trp Ser Arg Thr
Trp Ser Thr Arg
Trp Ser Trp Ala
Trp Thr Asp Lys
Trp Thr Gly Trp
Trp Thr Lys Asp
Trp Thr Arg Ser
Trp Thr Ser Arg
Trp Thr Trp Gly
Trp Val Met Asn
Trp Val Asn Met
Trp Trp Ala Ser
Trp Trp Gly Thr
Trp Trp Ser Ala
Trp Trp Thr Gly
Tyr His Met Val
Tyr His Val Met
Tyr Met His Val
Tyr Met Val His
Tyr Asn Pro Arg
Tyr Asn Arg Pro
Tyr Pro Asn Arg
Tyr Pro Arg Asn
Tyr Arg Asn Pro
Tyr Arg Pro Asn
Tyr Val His Met
Tyr Val Met His
PKOHA-PA
C26H45O10P (548.2750199999999)
15alpha-acetoxy-5alpha-chloro-6beta,14beta,dihydroxy-1-oxo-witha2,24-dien-26,22-olide
3-[2-(3-hydroxyphenyl)ethyl]-4-[2-[6-(2-phenylethylamino)hexylamino]ethyl]benzene-1,2-diol,dihydrochloride
ICG-001
C33H32N4O4 (548.2423431999999)
Murabutide
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents D007155 - Immunologic Factors
Imazamethabenz
Herbicidal metabolite of imazamethabenz-methyl. Acetolactate synthase inhibitor
butane-1,4-diol,ethane-1,2-diol,hexanedioic acid,1-isocyanato-4-[(4-isocyanatophenyl)methyl]benzene
(6R,9aR)-6-[(4-hydroxyphenyl)methyl]-8-(1-naphthalenylmethyl)-4,7-dioxo-N-(phenylmethyl)-3,6,9,9a-tetrahydro-2H-pyrazino[1,2-a]pyrimidine-1-carboxamide
C33H32N4O4 (548.2423431999999)
[(1R,3S,4R,4aR,5S,7R,8S,8aR)-8-[(3aS,5S,6aS)-3a,4,5,6a-tetrahydrofuro[2,3-b]furan-5-yl]-5-acetyloxy-4a-(acetyloxymethyl)-3-hydroxy-7,8-dimethylspiro[2,3,5,6,7,8a-hexahydro-1H-naphthalene-4,2-oxirane]-1-yl] (E)-2-methylbut-2-enoate
Terbutaline sulfate
D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013566 - Sympathomimetics C78273 - Agent Affecting Respiratory System > C29712 - Anti-asthmatic Agent > C319 - Bronchodilator C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists D012102 - Reproductive Control Agents > D015149 - Tocolytic Agents
Citrinin
Citrinin is practically insoluble (in water) and an extremely strong acidic compound (based on its pKa). Citrinin can be found in barley and common wheat, which makes citrinin a potential biomarker for the consumption of these food products. Citrinin is a mycotoxin which is often found in food. It is a secondary metabolite produced by fungi that contaminate long-stored food and it causes different toxic effects, like nephrotoxic, hepatotoxic and cytotoxic effects. Citrinin is mainly found in stored grains, but sometimes also in fruits and other plant products .
Tamoxifen-N-glucuronide
Tamoxifen-N-glucuronide is a metabolite of tamoxifen. Tamoxifen is an antagonist of the estrogen receptor in breast tissue via its active metabolite, hydroxytamoxifen. In other tissues such as the endometrium, it behaves as an agonist, and thus may be characterized as a mixed agonist/antagonist. Tamoxifen is the usual endocrine therapy for hormone receptor-positive breast cancer in pre-menopausal women, and is also a standard in post-menopausal women although aromatase inhibitors are also frequently used in that setting. (Wikipedia)
[(2R,6S,7R,8R)-3-[(3-formamido-2-hydroxybenzoyl)amino]-8-hexyl-2,6-dimethyl-4,9-dioxo-1,5-dioxonan-7-yl] 3-methylbutanoate
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents D000890 - Anti-Infective Agents > D000935 - Antifungal Agents
(2S,3S,4S,5R)-6-[(3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-2-[(2R)-4-[(1R)-2,6,6-trimethyl-4-oxocyclohex-2-en-1-yl]butan-2-yl]oxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid
Butyl 2-[2-[2-(2-acetamido-4,5,6-trihydroxy-1-oxohexan-3-yl)oxypropanoylamino]propanoylamino]-5-amino-5-oxopentanoate
3-methylbutanoic acid [(2R,6S,7R,8R)-3-[[(3-formamido-2-hydroxyphenyl)-oxomethyl]amino]-8-hexyl-2,6-dimethyl-4,9-dioxo-1,5-dioxonan-7-yl] ester
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents D000890 - Anti-Infective Agents > D000935 - Antifungal Agents
(3S,6S,7R,8aR)-6-[3-(2-hydroxyethoxy)phenyl]-N-[5-[(2-mercapto-1-oxoethyl)amino]pentyl]-3-(2-methylpropyl)-1,4-dioxo-2,3,6,7,8,8a-hexahydropyrrolo[1,2-a]pyrazine-7-carboxamide
1-[(2S,3S)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-3-[4-(trifluoromethyl)phenyl]urea
1-[(2R,3R)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-3-[4-(trifluoromethyl)phenyl]urea
1-[(2S,3R)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-3-[4-(trifluoromethyl)phenyl]urea
1-[(2S,3R)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-3-[4-(trifluoromethyl)phenyl]urea
N-[(2R,3R)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-(2-thiazolyl)benzamide
(2R)-2-[(4S,5R)-8-[2-(2-methoxyphenyl)ethynyl]-4-methyl-5-[[methyl-(phenylmethyl)amino]methyl]-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol
(2S)-2-[(4S,5R)-8-[2-(2-methoxyphenyl)ethynyl]-4-methyl-5-[[methyl-(phenylmethyl)amino]methyl]-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol
[1-[(2-acetyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate
C26H45O10P (548.2750199999999)
[1-[(2-butanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate
C26H45O10P (548.2750199999999)
[1-acetyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate
C26H45O10P (548.2750199999999)
[1-butanoyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate
C26H45O10P (548.2750199999999)
(2r,3'r,4'ar,5's,6'r,6'ar,10'ar,10'br)-5'-(acetyloxy)-6'a-[(acetyloxy)methyl]-4'a,10'b-dimethyl-5''-oxo-octahydrodispiro[oxirane-2,7'-naphtho[2,1-b]pyran-3',3''-oxolan]-6'-yl (2e)-2-methylbut-2-enoate
n-[2,6-dimethyl-8-(3-methylbutyl)-7-[(4-methylpentanoyl)oxy]-4,9-dioxo-1,5-dioxonan-3-yl]-2-hydroxy-3-[(hydroxymethylidene)amino]benzenecarboximidic acid
n-{7-hexyl-4,9-dimethyl-8-[(3-methylbutanoyl)oxy]-2,6-dioxo-1,5-dioxonan-3-yl}-2-hydroxy-3-[(hydroxymethylidene)amino]benzenecarboximidic acid
{[(4e,8s,9s,10e,12s,13r,14s,16r)-3,13,22-trihydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-19,20-dioxo-2-azabicyclo[16.3.1]docosa-1(21),2,4,10,18(22)-pentaen-9-yl]oxy}methanimidic acid
7-ethenyl-12-ethyl-21-hydroxy-6,11,27,28-tetramethyl-20-oxa-2,16,29,30-tetraazaheptacyclo[15.8.1.1³,²⁵.1⁵,⁸.1¹⁰,¹³.1¹⁵,¹⁸.0²¹,²⁶]triaconta-1,3,5,7,9,11,13(29),14,17(26),18(28)-decaene-19,22-dione
C33H32N4O4 (548.2423431999999)